Medical practices that are targeted to individuals on the basis of their specific genetic makeup, or personalized medicine, will soon be a reality, and government, industry, researchers, practitioners and the public must be prepared. HHS recently issued a report on personalized medicine, "Personalized Health Care: Opportunities, Pathways, Resources," which outlines the work that lies ahead for the government, the biotechnology and pharmaceutical industries, and other stakeholders. The potential for predicting health, for preventing and preempting disease, and for personalizing treatment according to each person s unique biology will have tremendous consequences for the healthcare system as a whole. Of particular importance are the implications for commercialization strategies for new and emerging medical technologies (biotechnology, med-tech devices, medical imaging and diagnostic testing), and the commensurate implications for patients.

This 90-minute interactive audio conference will, led by dynamic expert Dan Mendelson, president and founder of Avalere Health, will explore the impact of personalized medicine on companies and organizations of all sizes. It is scheduled for Tuesday, November 27, 2007, from 1 to 2:30 p.m. EST.

During this audio conference, you will learn:

  • How will the emergence of personalized medicine affect pharmaceutical pricing and commercialization strategy? How will it affect the commercial behavior of insurance companies?
  • What are the implications for pharmaceutical and med-tech testing and will personalized medicine make it more expensive or less expensive to test new products?
  • Will health information technology help facilitate personalized medicine over the coming decade? Given the current state of evolution, how realistic is fundamental change in health information technology?
  • How will all of the above trends affect patients?
  • Plus you'll get the chance to ask the speaker your own questions prior to the audio conference as well as during the live Q&A session following the presentation!

Who Should Attend:

  • Med-tech, biotech and pharmaceutical executives
  • Government affairs staff at healthcare practitioner associations
  • Patent and intellectual property attorneys
  • Medical product and pharmaceutical consultants
  • Executives with start-up and development-stage companies
  • Federal and state healthcare officials

    • Click here for more information or to register, or please call us toll-free at 800-688-2421.